Research programme: interleukin-12/STAT4 transcription factor inhibitors - Diakine Therapeutics

Drug Profile

Research programme: interleukin-12/STAT4 transcription factor inhibitors - Diakine Therapeutics

Alternative Names: C-9; DT 22669; DT 23552; ISLT-2669; ISLT-LSF analogs; ISLT-LSF analogues; Lisofylline analogs; Lisofylline analogues

Latest Information Update: 10 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Virginia
  • Developer DiaKine Therapeutics; National Institute of Diabetes and Digestive and Kidney Diseases
  • Class Small molecules
  • Mechanism of Action Immunomodulators; Interleukin 12 inhibitors; STAT4 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic nephropathies; Diabetic retinopathy; Latent autoimmune diabetes in adults; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 10 Dec 2015 Preclinical development is ongoing in USA
  • 23 Mar 2012 DiaKine Therapeutics has been acquired by Islet Sciences
  • 17 Oct 2007 Preclinical trials in Diabetic nephropathies in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top